LON:DXRX Diaceutics (DXRX) Share Forecast, Price & News GBX 98.10 -5.90 (-5.67%) (As of 10:52 AM ET) Add Compare Share Share Today's Range 98.10▼ 10450-Day Range 93▼ 10952-Week Range 74▼ 118Volume26,474 shsAverage Volume56,527 shsMarket Capitalization£82.87 millionP/E Ratio10,500.00Dividend YieldN/APrice TargetGBX 150 ProfileProfileAnalyst RatingsChartCompetitorsInsider TradesHeadlinesProfileAnalyst RatingsChartCompetitorsInsider TradesHeadlines About Diaceutics (LON:DXRX) StockDiaceutics PLC, a diagnostic commercialisation company, provides data, data analytics, and implementation services for pharmaceutical companies worldwide. It operates DXRX platform, which offers DXRX data solutions, including access to various pipelines of diagnostic testing data from a network of laboratories that provides DXRX signal, lab mapping, testing dashboard, and physician mapping services; DXRX marketplace solutions, which enables a marketplace, where labs, pharma, and diagnostic companies come to find partners for collaborations on precision medicine diagnostics. The company also provides DXRX lab education, a suite of tailored and targeted training sessions designed to provide essential education for labs to enable and drive quality testing and biomarker knowledge; DXRX advisory boards that create and enable a valuable interface for pharmaceutical companies with a view to exploring and revealing new insights pertinent to the commercialisation and development of a therapy or companion diagnostic; and DXRX Lab Alerts, an advanced laboratory targeting service delivering tailored, short-form, quick read, educational messages with call-to-action to labs in the DXRX network. In addition, it offers implementation and consulting services for precision medicine diagnostics. Diaceutics PLC was incorporated in 2005 and is headquartered in Belfast, the United Kingdom.Read More DXRX Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart DXRX Stock News HeadlinesSeptember 27, 2023 | americanbankingnews.comDiaceutics (LON:DXRX) Receives "Buy" Rating from Canaccord Genuity GroupApril 20, 2023 | finance.yahoo.comDiaceutics PLC (LON:DXRX) Stock Is Going Strong But Fundamentals Look Uncertain: What Lies AheadOctober 4, 2023 | Wall Street Fundamentals (Ad)Would Buffett Approve of This Growth Strategy?Warren Buffett's approach has been to find and invest in undervalued businesses with strong potential for growth. Taking this approach to heart and applying it to a Trillion Dollar industry has proved itself in a big way...achieving an incredible 400+% growth during a down market.April 20, 2023 | finance.yahoo.comDiaceutics PLC (LON:DXRX) Stock Is Going Strong But Fundamentals Look Uncertain: What Lies Ahead ?April 17, 2023 | marketwatch.comDiaceutics 2022 Pretax Profit Rose on Growing DemandMarch 13, 2023 | marketwatch.comDiaceutics Suspends Share Trading as SVB Closure Restricts Access to Its FundsMarch 10, 2023 | finance.yahoo.comThose who invested in Diaceutics (LON:DXRX) a year ago are up 13%January 28, 2023 | finance.yahoo.comBroker Revenue Forecasts For Diaceutics PLC (LON:DXRX) Are Surging HigherOctober 4, 2023 | Wall Street Fundamentals (Ad)Would Buffett Approve of This Growth Strategy?Warren Buffett's approach has been to find and invest in undervalued businesses with strong potential for growth. Taking this approach to heart and applying it to a Trillion Dollar industry has proved itself in a big way...achieving an incredible 400+% growth during a down market.January 27, 2023 | lse.co.ukTRADING UPDATES: Diaceutics wins two deals; Faron proposes placingDecember 9, 2022 | finance.yahoo.comAn Intrinsic Calculation For Diaceutics PLC (LON:DXRX) Suggests It's 40% UndervaluedNovember 28, 2022 | msn.comDanske Bank supported the purchase of the new building at Kings Hall Life Sciences ParkSeptember 29, 2022 | finance.yahoo.comEdited Transcript of DXRX.L earnings conference call or presentation 28-Sep-22 12:00pm GMTSeptember 16, 2022 | nz.finance.yahoo.comDEWA and WGEO Complete Preparations for 8th Edition of the World Green Economy SummitSeptember 16, 2022 | yahoo.comBake Off star Laura Adlington reveals she was left suicidal after trolls fat-shamed her on social mediaAugust 14, 2022 | uk.finance.yahoo.comDiaceutics PLC (DXRX.L)July 2, 2022 | finance.yahoo.comIs Diaceutics PLC (LON:DXRX) Trading At A 32% Discount?June 13, 2022 | lse.co.ukDiaceutics wins USD2 million contract with "top five global" drug firmMay 23, 2022 | finance.yahoo.comDiaceutics PLC (LON:DXRX) Has Varied Financials: Could That Be Why Its Recent Performance Has Been Uneventful?May 5, 2022 | lse.co.ukDiaceutics inks five-year deal with existing pharma partnerApril 7, 2022 | finance.yahoo.comThe past year for Diaceutics (LON:DXRX) investors has not been profitableMarch 22, 2022 | lse.co.ukDiaceutics returns to pretax profit in 2021 and ups revenueMarch 16, 2022 | marketwatch.comDiaceutics Approved by US Agency to Receive Enhanced DataFebruary 14, 2022 | marketwatch.comDiaceutics Gets Three-Year Contract Worth More Than $2.5 MlnJanuary 25, 2022 | uk.news.yahoo.comIs this FTSE AIM stock primed for growth in 2022?January 11, 2022 | lse.co.ukDiaceutics hails DXRX platform for strong annual sales and earningsJanuary 11, 2022 | marketwatch.comDiaceutics Appoints Nick Roberts CFO, 2021 Revenue rose 10%See More Headlines Receive DXRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Diaceutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Industry, Sector and Symbol Stock ExchangeLON Industry Diagnostics & Research Sub-IndustryN/A SectorMedical Current SymbolLON:DXRX CUSIPN/A CIKN/A Webwww.diaceutics.com PhoneN/AFaxN/AEmployees151Year FoundedN/APrice Target and Rating Average Stock Price ForecastGBX 150 High Stock Price ForecastGBX 150 Low Stock Price ForecastGBX 150 Forecasted Upside/Downside+44.2%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E Ratio10,500.00 Forward P/E Ratio33.44 P/E GrowthN/ANet IncomeN/A Net Margins0.03% Pretax MarginN/A Return on Equity0.01% Return on Assets-0.72% Debt Debt-to-Equity Ratio3.07 Current Ratio7.99 Quick Ratio9.92 Sales & Book Value Annual Sales£21.90 million Price / Sales4.01 Cash FlowGBX 33.34 per share Price / Cash Flow3.12 Book ValueGBX 49 per share Price / Book2.12Miscellaneous Outstanding Shares84,470,000Free FloatN/AMarket Cap£87.85 million OptionableNot Optionable Beta0.36 12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?Get This Free Report Key ExecutivesMr. Peter Keeling (Age 61)Founder, CEO & Exec. Director Comp: $363.24kMr. Nicholas Stewart Roberts (Age 40)CFO & Director Comp: $180.37kMr. Ryan Keeling (Age 40)Chief Innovation Officer & Exec. Director Comp: $334.27kMs. Julie BrowneChief Operating OfficerMs. Gillian ShawGen. CounselMs. Jillian BeggsVP of Sales & MarketingMs. Norma ThompsonGlobal Head of HRMr. Jordan ClarkChief Commercial OfficerMs. Susanne MunkstedChief Precision Medicine OfficerMs. Marieke HoefsmitSr. Director & Head of Data Delivery NetherlandsMore ExecutivesKey CompetitorsANGLELON:AGLLungLife AILON:LLAIINSPECS GroupLON:SPECShield TherapeuticsLON:STXMereo BioPharma Group plc (MPH.L)LON:MPHView All CompetitorsInsidersNick RobertsBought 139 shares on 8/29/2023Total: £139.00 ($1.00/share)Nick RobertsBought 21,742 shares on 6/5/2023Total: £2.00 M ($92.00/share)Nick RobertsBought 183 shares on 5/30/2023Total: £15,006.00 ($82.00/share)Nick RobertsBought 130 shares on 2/28/2023Total: £14,950.00 ($115.00/share)Nick RobertsBought 153 shares on 1/27/2023Total: £14,994.00 ($98.00/share)View All Insider Transactions DXRX Stock - Frequently Asked Questions Should I buy or sell Diaceutics stock right now? 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Diaceutics in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" DXRX shares. View DXRX analyst ratings or view top-rated stocks. What is Diaceutics' stock price forecast for 2023? 2 brokers have issued twelve-month price objectives for Diaceutics' shares. Their DXRX share price forecasts range from GBX 150 to GBX 150. On average, they anticipate the company's stock price to reach GBX 150 in the next twelve months. This suggests a possible upside of 44.2% from the stock's current price. View analysts price targets for DXRX or view top-rated stocks among Wall Street analysts. How have DXRX shares performed in 2023? Diaceutics' stock was trading at GBX 75.50 at the start of the year. Since then, DXRX shares have increased by 37.7% and is now trading at GBX 104. View the best growth stocks for 2023 here. What is Diaceutics' stock symbol? Diaceutics trades on the London Stock Exchange (LON) under the ticker symbol "DXRX." How do I buy shares of Diaceutics? Shares of DXRX stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.Compare Top Brokerages Here. What is Diaceutics' stock price today? One share of DXRX stock can currently be purchased for approximately GBX 104. How much money does Diaceutics make? Diaceutics (LON:DXRX) has a market capitalization of £87.85 million and generates £21.90 million in revenue each year. How many employees does Diaceutics have? The company employs 151 workers across the globe. This page (LON:DXRX) was last updated on 10/4/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Diaceutics PLC Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.